



Pure Bioscience shares rise on antibacterial study

By The Associated Press

Thursday, May 19, 2011

Sanitizer developer Pure Bioscience (Nasdaq: PURE) said Thursday that its antibacterial formula appears effective against a bacterial film linked to various infections.

Company shares climbed 34 cents, or 33 percent, to \$1.37 in morning trading.

The company said laboratory tests showed its silver dehydrate citrate killed two leading biofilms within minutes. Biofilm is a collection of bacterial cells held together by slime produced by the bacteria. The germs play a role in gum disease, pneumonia, prostate infections, kidney stones and other infections.

Pure Bioscience's dehydrate citrate is a form of ionic silver that the company is developing to kill germs in hospital, agricultural and industrial settings.